Last $7.91 USD
Change Today -0.04 / -0.50%
Volume 356.1K
CYTK On Other Exchanges
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/14 - $13.26
52 Week Low
10/13/14 - $3.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTOKINETICS INC (CYTK)

cytokinetics inc (CYTK) Related Businessweek News

No Related Businessweek News Found

cytokinetics inc (CYTK) Details

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to develop a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

cytokinetics inc (CYTK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $555.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $391.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $388.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $347.5K
Senior Vice President of Human Resources
Total Annual Compensation: $278.0K
Compensation as of Fiscal Year 2013.

cytokinetics inc (CYTK) Key Developments

Cytokinetics, Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015; Expects to Initiate Phase III Clinical Development Program in the Second Quarter of 2015 and Phase II Trial of Ck-2127107 in Patients with SMA in the Second Half of 2015

Cytokinetics, Incorporated reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of USD 21,758,000 against USD 24,349,000 a year ago. Operating income was USD 8,421,000 against USD 6,432,000 a year ago. Net income was USD 8,443,000 against USD 6,531,000 a year ago. Diluted net income per share was USD 0.23 against USD 0.21 a year ago. For the year, the company reported total revenues of USD 46,940,000 against USD 30,648,000 a year ago. Operating loss was USD 14,754,000 against USD 33,894,000 a year ago. Net loss was USD 14,646,000 against USD 33,717,000 a year ago. Basic and diluted net loss per share was USD 0.41 against USD 1.24 a year ago. The company also announced its financial guidance for 2015. The company anticipates cash revenue will be in the range of USD 40 to USD 43 million. This guidance includes approximately USD 30 million in revenue which will be deferred and recognized over a two year period ending in 2016 under generally accepted accounting principles. This guidance excludes the USD 15 million milestone payment earned in 2014 from Astellas and an estimated USD 3.6 million in non-cash related operating expenses primarily related to stock compensation expense. The company expects to initiate a Phase III clinical development program for tirasemtiv in patients with ALS in the second quarter of 2015. The company expects to initiate a Phase II trial of CK-2127107 in patients with SMA in the second half of 2015. The company expects enrollment of patients in the expansion phase of COSMIC-HF to conclude in the first quarter of 2015 and results from COSMIC-HF to be available in the second half of 2015. The company also expects to continue joint development activities in collaboration with Amgen directed to the potential advancement of omecamtiv mecarbil to Phase III clinical development.

Denise M. Gilbert Not to Stand for Reelection to the Board of Directors of Cytokinetics, Incorporated

On February 9, 2015, Denise M. Gilbert, Ph.D. provided notice to Cytokinetics, Incorporated that she will not stand for re-election to the company's Board of Directors at the company's Annual Meeting of Stockholders, which will occur on May 20, 2015. Dr. Gilbert has indicated she will continue her service on the Board until the expiration of her current term.

Cytokinetics, Incorporated to Report Q4, 2014 Results on Feb 12, 2015

Cytokinetics, Incorporated announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $7.91 USD -0.04

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.04 USD +0.13
CTI BioPharma Corp $2.72 USD +0.26
Curis Inc $3.33 USD +0.17
Evotec AG €3.70 EUR +0.009
Exelixis Inc $3.11 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at